Interestingly, microPTCs or the presence of underlying HT had 91% (OR = 0.09, 95%CI = 0.02–0.41; p < 0.001) and 76% (OR = 0.24, 95%CI = 0.08–0.78; p < 0.01) decreased odds of developing LNM in patients with BRAF mutant PTC. This evidence concerns the gene BRAF and hematocrit.